PMID- 11426633
OWN - NLM
STAT- MEDLINE
DCOM- 20010927
LR  - 20190116
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 40
IP  - 1-2
DP  - 2000 Dec
TI  - A prospective randomized study of Chop versus Chop plus alpha-2B interferon in 
      patients with intermediate and high grade non-Hodgkin's lymphoma: the 
      International Oncology Study Group NHL1 Study .
PG  - 95-103
AB  - The addition of a brief alpha interferon regimen to each CHOP induction cycle, 
      plus one year of alpha interferon thrice weekly maintenance therapy, has no early 
      effect on response rates or survival in patients with Intermediate or High grade 
      cell NHL. BACKGROUND: The CHOP (Cyclophosphamide, Adriamycin. Vincristine, 
      Prednisone) regimen is the most widely used first-line therapy for patients with 
      Intermediate or High Grade (IG/HG) non-Hodgkin's lymphoma (NHL). Alpha 2b 
      interferon (INF) enhances response rates and improves survival in low-grade NHL. 
      The International Oncology Study Group (IOSG) conducted a prospective randomized 
      study comparing CHOP alone or combined with INF in patients with IG/HG-NHL. The 
      primary study aim was to compare the objective response rates in these patient 
      cohorts. PATIENTS AND METHODS: Patients with a confirmed diagnosis of measurable 
      NHL of International Working Formulation (IWF) groups D to H histology were 
      randomized to receive CHOP alone or CHOP with 5Mu INF s.c. for 5 days on days 22 
      to 26 of each 28 day cycle with INF 5 million units (Mu) given three times per 
      week subcutaneously for 52 weeks in those patients who responded to CHOP plus 
      INF. RESULTS: The overall response rates were equivalent in both groups: CHOP 
      alone (214 patients) 81% (complete 55%, partial 26%); CHOP plus INF (221 
      patients) 80% (complete 54%, partial 26%). At 36 months, the actuarial survival 
      rate was equivalent in both groups. CONCLUSIONS: There is no apparent early 
      advantage in terms of response or survival conferred by adding the study INF 
      regimen to CHOP therapy for patients with IG/HG-NHL.
FAU - Giles, F J
AU  - Giles FJ
AD  - International Oncology Study Group, Houston, Texas, USA. frankgiles@aol.com
FAU - Shan, J
AU  - Shan J
FAU - Advani, S H
AU  - Advani SH
FAU - Akan, H
AU  - Akan H
FAU - Aydogdu, I
AU  - Aydogdu I
FAU - Aziz, Z
AU  - Aziz Z
FAU - Azim, H A
AU  - Azim HA
FAU - Bapsy, P P
AU  - Bapsy PP
FAU - Buyukkececi, F
AU  - Buyukkececi F
FAU - Chaimongkol, B
AU  - Chaimongkol B
FAU - Chen, P M
AU  - Chen PM
FAU - Cheong, S K
AU  - Cheong SK
FAU - Ferhanoglu, B
AU  - Ferhanoglu B
FAU - Hamza, R
AU  - Hamza R
FAU - Khalid, H M
AU  - Khalid HM
FAU - Intragumtornchai, T
AU  - Intragumtornchai T
FAU - Kim, S W
AU  - Kim SW
FAU - Kim, S Y
AU  - Kim SY
FAU - Koc, H
AU  - Koc H
FAU - Kumar, L
AU  - Kumar L
FAU - Kumar, R
AU  - Kumar R
FAU - Lei, K I
AU  - Lei KI
FAU - Lekhakula, A
AU  - Lekhakula A
FAU - Muthalib, A
AU  - Muthalib A
FAU - Patel, M
AU  - Patel M
FAU - Poovalingam, V P
AU  - Poovalingam VP
FAU - Prayoonwiwat, W
AU  - Prayoonwiwat W
FAU - Rana, F
AU  - Rana F
FAU - Reksodiputro, A H
AU  - Reksodiputro AH
FAU - Ruff, P
AU  - Ruff P
FAU - Sagar, T G
AU  - Sagar TG
FAU - Schwarer, A P
AU  - Schwarer AP
FAU - Song, H S
AU  - Song HS
FAU - Suh, C W
AU  - Suh CW
FAU - Suharti, C
AU  - Suharti C
FAU - Supindiman, I
AU  - Supindiman I
FAU - Tee, G Y
AU  - Tee GY
FAU - Thamprasit, T
AU  - Thamprasit T
FAU - Villalon, A H
AU  - Villalon AH
FAU - Wickham, N R
AU  - Wickham NR
FAU - Wong, J E
AU  - Wong JE
FAU - Yalcin, A
AU  - Yalcin A
FAU - Jootar, S
AU  - Jootar S
CN  - International Oncology Study Group NHL1 Study
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - CHOP protocol
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use/toxicity
MH  - Cyclophosphamide/administration & dosage/toxicity
MH  - Doxorubicin/administration & dosage/toxicity
MH  - Female
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/*administration & dosage/toxicity
MH  - Lymphoma, Non-Hodgkin/complications/*drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Prednisone/administration & dosage/toxicity
MH  - Prospective Studies
MH  - Recombinant Proteins
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Vincristine/administration & dosage/toxicity
EDAT- 2001/06/28 10:00
MHDA- 2001/09/28 10:01
CRDT- 2001/06/28 10:00
PHST- 2001/06/28 10:00 [pubmed]
PHST- 2001/09/28 10:01 [medline]
PHST- 2001/06/28 10:00 [entrez]
AID - 10.3109/10428190009054885 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2000 Dec;40(1-2):95-103. doi: 10.3109/10428190009054885.